SELECTED PUBLICATIONS
1. Shu Y, Rai A, Sizemore GM, Ostrowski M, Huang W, Mehta KD (2025)
Hepatic protein kinase Cβ antagonizing p38 MAPK to activate ERK1/2 to dysregulate biliary lipid composition upon lithogenic stress. American Journal of Physiology, Gastroenterology, and Liver Physiology. 329: G653–G663, 2025.
https://journals.physiology.org/doi/pdf/10.1152/ajpgi.00208.2025
2. Shu Y, Gumma N, Hassan F, Branch DA, Baer LA, Ostrowski MC, Stanford KI, Baskin KK, Mehta KD (2023)
Hepatic PKCβ deficiency mitigates late-onset obesity. J. Biol. Chem., 299:104917.
https://pubmed.ncbi.nlm.nih.gov/37315788/
3. Mehta KD (2022)
A novel PKCβ inhibitor more potent than ruboxistaurin: Potential therapeutic tool for obesity and fatty liver disease. FASEB J., 36:R1984.
https://doi.org/10.1096/fasebj.2022.36.S1.R1984
4. Shu Y, Hassan F, Ostrowski M, Mehta KD (2021)
Role of hepatic PKCβ in nutritional regulation of hepatic glycogen synthesis. JCI Insight, 6(19):e149023.
https://doi.org/10.1172/jci.insight.149023
5. Shu Y, Hassan F, Coppola V, Baskin KK, Han H, Mehta NK, Ostrowski M, Mehta KD (2021)
Hepatocyte-specific PKCβ deficiency protects against high-fat diet-induced non-alcoholic hepatic steatosis. Mol. Metab., 44:e101133.
https://doi.org/10.1016/j.molmet.2020.101133
6. Huang W, Mehta D, Sif S, Kent LN, Jacob ST, Ghoshal K, Mehta KD (2017)
Dietary fat/cholesterol-sensitive PKCβ-RB signaling: Potential role in NASH/HCC axis. Oncotarget, 8:73757–73765.
https://pmc.ncbi.nlm.nih.gov/articles/PMC5650297/
7. Huang W, Mehta KD (2015)
Modulation of hepatic PKCβ in metabolic adaptation to a lithogenic diet. Cell. Mol. Gastroenterol. Hepatol., 1:395–405.
https://pubmed.ncbi.nlm.nih.gov/28210689/
8. Patergnani S, Marchi S, Rimessi A, Bonora M, Mehta KD, Pinton P (2013)
The protein kinase Cβ and the mitochondrial axis as key regulators of autophagy. Autophagy, 9:1367–1385.
https://pubmed.ncbi.nlm.nih.gov/23778835/
9. Huang W, Bansode R, Bal N, Mehta KD (2012)
Ablation of PKCβ attenuates obesity syndrome of ob/ob mice by promoting WAT remodeling. J. Lipid Res., 53:368–378.
https://pubmed.ncbi.nlm.nih.gov/22210924/
10. Huang W, Bansode R, Mehta KD (2009)
Loss of protein kinase Cβ protects mice against diet-induced obesity, hepatic steatosis and insulin resistance. Hepatology, 49:1525–1536.
https://pubmed.ncbi.nlm.nih.gov/19296465/
11. Bansode RR, Huang W, Roy SK, Mehta KD (2008)
Protein kinase Cβ deficiency increases fatty acid oxidation and reduces fat storage. J. Biol. Chem., 283:231–236.
RECENT CONFERENCE PRESENTATIONS
Mehta KD (2022) Preclinical efficacy of INST3399, a synthetic novel PKCβ inhibitor for treatment of obesity and fatty liver disease. June 14-16, 2022. NUTRITION 2022 LIVE ONLINE.
McCarthy F, Mehta KD (2022) Identification of a novel bisindolylmaleimide derivative with potent PKCβ inhibition than ruboxistaurin with implications for obesity. International Conference on Fatty Liver, April 28-30, 2022, Vienna, Austria.
Mehta KD (2022) A novel PKCβ inhibitor more potent than ruboxistaurin: Potential therapeutic tool for obesity and fatty liver disease. Experimental Biology 2022, April 2-5, 2022, Philadelphia, PA.
Yaoling S, Hassan F, Sanford K, Ostrowski M, Baskin K, Mehta KD (2019) Hepatic protein kinase Cβ regulates liver cross-talk with peripheral tissues for controlling energy expenditure. Nature: Advances in Metabolic Communication. October 14-18, 2019, Rio de Janeiro, Brazil.
Hassan F, Yaoling S, Coppola V, Stanford K, Baskin K, Ostrowski M, Mehta KD (2019) Hepatic protein kinase Cβ deficiency protects from high-fat diet induced obesity and hepatic steatosis. Integrated Pathways of Disease in NASH and NAFLD. Keystone Symposia, January 20-24, 2019, Santa Fe, New Mexico.